Harvard Bioscience, Inc. — FY2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013. The filing is an annual report, not a standalone fourth-quarter filing. Unless noted, amounts are in U.S. dollars; financial results are presented with HART as discontinued operations for all periods shown.
Business context and reporting period
Harvard Bioscience develops, manufactures and markets life-science research instruments, systems and laboratory consumables, selling in more than 100 countries. After spinning off its regenerative medicine business, Harvard Apparatus Regenerative Technology, Inc. (HART), on November 1, 2013, the company focused on its Life Science Research Tools business and reported one operating segment. The company distributed one HART share for every four Harvard Bioscience shares and contributed approximately $15.0 million in cash to HART.
Financial performance and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $105.2 million | $111.2 million |
| Gross profit / margin | $47.7 million / 45.4% | $52.3 million / 47.1% |
| Operating income | $1.5 million | $7.8 million |
| Income from continuing operations | $0.7 million | $4.5 million |
| Net income (loss) | $(1.8) million | $2.4 million |
| Cash from operating activities | $4.1 million | $8.1 million |
| Cash and cash equivalents at year-end | $25.8 million | $20.7 million |
| Debt outstanding at year-end | $24.8 million | $13.0 million |
| Working capital | $44.7 million | $49.1 million |
FY2013 net loss included a $2.6 million loss from discontinued operations. Fourth-quarter revenue was $27.9 million; operating loss was $0.9 million and net loss was $0.8 million. The filing reports no separate quarterly cash-flow or liquidity measures.
Cash less debt was approximately $1.0 million at year-end, versus $7.7 million in 2012. Of the $25.8 million cash balance, $23.6 million was held by foreign subsidiaries and was not available for U.S. operations without repatriation, which could trigger taxes. The company reported $17.4 million of available borrowing capacity, subject to a working-capital borrowing restriction, and compliance with all financial covenants at year-end.
Material changes and unusual items
- Revenue declined 5.4%; excluding currency and acquisition effects, management reported a 5.8% decline. It cited U.S. government sequestration, uncertainty and budget constraints in several European markets, and lower sales associated with GE Healthcare.
- Gross margin fell 1.7 percentage points, primarily due to discontinued/obsolete inventory adjustments, lower volume and product mix.
- Operating expenses included $2.2 million of restructuring charges and $2.0 million of HART separation costs. The restructuring included an approximately 13% workforce reduction.
- Debt increased by $11.8 million net during the year, while cash flow from operations fell by approximately half. The company transferred $15.0 million to HART and received $1.8 million related to the final UBI earn-out payment.
Outlook, risks and contingencies
Management expected the restructuring to generate approximately $2.0 million of annual pre-tax savings beginning in 2014, after approximately $1.0 million of reinvestment. It expected available cash, operating cash generation and debt capacity to support current operations and capital expenditures for at least 12 months; this is a forward-looking estimate, not a guarantee. Planned 2014 capital expenditures were approximately $1.6 million. No numerical revenue or earnings guidance was provided.
Key risks include exposure to government and research funding, pharmaceutical and biotechnology spending, international markets and currency fluctuations; variable-rate debt, covenant restrictions and secured lender claims on substantially all assets; and execution risks from restructuring, new management and expansion into Asia. The company also disclosed that tax-free treatment of the HART spin-off depends on continuing to satisfy relevant representations and restrictions, which may constrain certain transactions. Risk disclosures mention correspondence from Nanofiber Solutions concerning intellectual property and a scaffold product now owned and developed by HART; the filing separately says Harvard Bioscience was not party to material legal proceedings at the reporting date. Management reported no impairment of goodwill or intangible assets, and management and the auditor concluded internal control over financial reporting was effective.
Investor facts to verify
- Whether the projected $2.0 million restructuring savings are achieved and whether additional restructuring costs arise.
- How revenue, gross margin and operating performance trend after the HART spin-off, particularly in government-funded and European markets.
- Debt, covenant headroom and the availability of cash held overseas for domestic obligations.
- The status and potential financial or tax consequences of HART-related tax covenants and the disclosed intellectual-property correspondence.
- Whether cash generation and management’s liquidity expectations remain adequate as debt repayments come due.